Table 3.
Major adverse clinical outcomes among patients receiving warfarin for stroke prevention in AF, overall and in patients aged ≥80 and < 80 years.
| Outcomes, N (%) | Age ≥80, N = 205 | Event rate/100 pt-yrs | Age <80, N = 786 | Event rate/100 pt-yrs | p value for proportions |
|---|---|---|---|---|---|
| ≥1 MACE | 64 (31.2) | 8.4 | 265 (33.7) | 7.4 | 0.55 |
| Stroke/TIA/SE | 12 (5.9) | 1.4 | 38 (4.8) | 0.9 | 0.68 |
| Bleeding∗ | 21 (10.2) | 2.4 | 57 (7.3) | 1.3 | 0.16 |
| Cardiovascular hospitalisation‡ | 38 (18.5) | 4.7 | 188 (23.9) | 5.0 | 0.12 |
| Death | 8 (3.9) | 0.9 | 15 (1.9) | 0.3 | 0.15 |
MACE: major adverse clinical events, SE: systemic embolism, TIA: transient ischemic attack, yrs: years. ∗Bleeding is combination of major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) and clinically relevant nonmajor bleed (CRNMB). ‡Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: (i) heart failure, myocardial infarction, new angina, nonfatal cardiac arrest, ventricular arrhythmia, uncontrolled atrial fibrillation/atrial flutter, and supraventricular arrhythmia; (ii) valve surgery, coronary artery bypass graft surgery (CABG), percutaneous transluminal coronary angioplasty (PTCA) surgery, pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, and limb amputation and as recorded in the patient's medical documents; DVT: deep vein thrombosis; major bleeding: ISTH major bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial or intramuscular with compartment syndrome and/or bleeding causing a fall in the haemoglobin level of 2 g/dL (1.24 mmol/L) or more or leading to transfusion of two or more units of whole blood or red cells; clinically relevant nonmajor bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major bleeding and that led to hospitalisation, physician medical or surgical treatment, or a change in antithrombotic therapy; PE: pulmonary embolism; SE: systemic embolism; TIA: transient ischemic attack; VTE: venous thromboemboli.